why choose us

First received: December 15, 2022

Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Transthyretin-Mediated Amyloidosis

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneously Administer

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.

Read more